Imbruvica 140mg Capsule 120's

Imbruvica 140mg Capsule contains the active ingredient Ibrutinib. It is indicated for treatment of blood cancers including mantle cell lymphoma (MCL), chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL), Waldenström macroglobulinemia, and marginal zone lymphoma (MZL). These are cancers of white blood cells called lymphocytes, which form part of the immune system. They differ by the location of cancer occurrence, the type of lymphocytes affected, and other specific factors. Imbruvica 140mg Capsule is also used to treat chronic graft versus host disease (cGvHD) following failure of systemic therapy. During allogeneic stem cell transplantation, patients receive stem cells from a donor. GvHD occurs when donor cells attack the patient's cells as foreign. Before taking Imbruvica 140mg Capsule, discuss with your doctor if you have bleeding disorders, infection, liver disease, heart disease, or intolerance to certain sugars. This medication is not recommended for children and adolescents. Inform your doctor if you have recently undergone or will undergo any surgical procedure. Your doctor may discontinue Imbruvica 140mg Capsule before any planned surgical or medical procedure. Use effective contraception during treatment and for at least one month after the final dose. Avoid grapefruit or oranges in any form during treatment; they may increase drug concentration in the blood. Drink adequate fluid to prevent dehydration. Inform your doctor if you experience persistent diarrhoea.

The Imbruvica 140 mg uses include: To treat mantle cell lymphoma In the treatment of chronic lymphocytic leukaemia (Blood cancer) To treat small lymphocytic lymphoma In the treatment of Waldenstrom’s macroglobulinemia To treat chronic graft vs. host disease after failure of systemic therapy

Imbruvica (Ibrutinib) 140mg Capsule is a Bruton’s tyrosine kinase (BTK) inhibitor used to treat blood cancers such as chronic lymphocytic leukaemia (CLL), mantle cell lymphoma (MCL), and Waldenström’s macroglobulinemia (WM). By blocking BTK signaling, it disrupts cancer cell survival, slows disease progression, and promotes apoptosis or programmed cell death. This targeted approach helps reduce tumour burden, improve patient outcomes, and enhance overall survival rates. Imbruvica is taken orally and provides a less invasive alternative to traditional chemotherapy, offering sustained disease control with long-term use.

Consume this medicine at the same time each day. While taking Imbruvica 140mg Capsule, do not consume grapefruit or orange in any form during the treatment. Drink plenty of fluid to prevent dehydration. Do not break or chew the capsule.

Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. The Imbruvica side effects include: Serious side effects of Imbruvica 140mg Capsule 120's are: Bleeding problems Infections Decrease in blood cell counts Heart problems High BP Secondary cancer Tumor lysis syndrome Severe allergic reactions Common side effects of Imbruvica 140mg Capsule 120's are: Nausea, vomiting, diarrhoea Tiredness Muscle and bone pain Rash and bruising Mouth sores Pneumonia Fever, chills Breathlessness Constipation Dizziness Body pain Swollen ankles and feet Increased creatinine levels in the blood Heavier periods and blood in urine Blurred vision Weakness and numbness

Contact your doctor immediately if you experience bleeding, infection, shortness of breath, or chest discomfort. Report to your doctor if you have had a history of heart failure or hepatitis infection. It is not recommended to take this medicine before or after surgery as it causes a delay in wound healing. Discuss effective contraceptive options with your healthcare provider and use them during treatment and for a month after the last dose of Imbruvica 140mg capsule.